WuXi Biologics has announced that its plans to expand the new state-of-the-art integrated biologics conjugation solution centre. The expansion will be to include commercial manufacturing at the Wuxi city, China location.
Bioconjugates such as Antibody-Drug Conjugates (ADCs) present new and exciting opportunities in treating various cancers. Last June, WuXi Biologics announced the building of an integrated biologics conjugation solution centre, including process development and clinical manufacturing for ADCs drug substance and drug product.
This centre is expected to initiate GMP manufacturing later this year. The new 5.5-acre expansion will enable cGMP commercial manufacturing for ADCs drug substance and drug product.
"We are quite excited to expand the construction of this new integrated biologics conjugation solution centre, which will further enhance our technical capabilities and manufacturing capacities in the fast-growing bioconjugation field," said Dr Chris Chen, CEO of WuXi Biologics. "With the strength of our ONE-stop service platform covering antibody, bioconjugation drug substance and drug product, WuXi Biologics will continue enabling our global partners to develop exciting ADCs to benefit cancer patients worldwide."
There are currently more than 20 ADCs being developed at WuXi Biologics. So far and the Chinese company has successfully advanced 11 projects to Investigational New Drug (IND) filing.
